Drug intelligence / Profile preview

NPH insulin + inhaled human insulin

Development stage
Discontinued
Lead developer
Mannkind
Administration
Subcutaneous, Inhalation
01

Overview

The combination of NPH insulin and inhaled human insulin represents a treatment approach for diabetes mellitus that pairs an intermediate-acting injectable insulin with a rapid-acting inhaled insulin formulation.\n\nNPH insulin (Neutral Protamine Hagedorn) serves as the basal insulin component, providing background insulin coverage for 12-18 hours. It typically peaks at 4-12 hours after injection and helps control blood glucose between meals and overnight[4].\n\nThe inhaled human insulin component (brand name Afrezza, formerly Exubera) is a dry powder form of rapid-acting insulin delivered by oral inhalation[2]. It starts working within 10-15 minutes, peaks at 35-45 minutes, and has a duration of 1.5-3 hours[4]. This rapid action makes it suitable for controlling mealtime blood glucose spikes.\n\n## Clinical Evidence\n\nClinical trials have demonstrated that this combination can provide effective glycemic control. In patients with type 1 diabetes, studies showed that inhaled insulin before meals plus ultralente insulin at night provided comparable glycemic control to conventional insulin regimens[3]. Similarly, in type 2 diabetes, the combination of inhaled insulin with basal insulin has shown effectiveness in controlling blood glucose levels[5].\n\n## Administration\n\nThe NPH insulin is administered subcutaneously, typically once or twice daily. The inhaled insulin is administered at the beginning of meals using a specialized inhaler device[1]. This combination reduces, but does not eliminate, the need for injections in patients with diabetes.\n\n## Safety Considerations\n\nCommon side effects of inhaled insulin include hypoglycemia, cough, throat pain, and potential decreases in pulmonary function[2][6]. Pulmonary function should be monitored during treatment, with baseline spirometry followed by repeat testing at six months and one year, with yearly follow-up thereafter[2]. Inhaled insulin is contraindicated in patients with chronic pulmonary diseases such as asthma and COPD[5].

Brand names
AfrezzaExubera
02

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on NPH insulin + inhaled human insulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NPH insulin + inhaled human insulin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call